Skip to Main Content
More Intelligent Procurement, Faster R&D

Go to Main Navigation

sc-166583 SAMPLE sc-166583

Promo Available Scientist.com Supplier

MAVS (E-3)

Santa Cruz Biotechnology

DESCRIPTION

mouse monoclonal IgG2a; MAVS Antibody (E-3) is an IgG2a κ mouse monoclonal MAVS antibody (also designated IPS1 antibody, or VISA antibody) that detects the MAVS protein of human origin by WB, IP, IF, IHC(P) and ELISA. MAVS Antibody (E-3) is available as both the non-conjugated anti-MAVS antibody form, as well as multiple conjugated forms of anti-MAVS antibody, including agarose, HRP, PE, FITC and multiple Alexa Fluor® conjugates. MAVS (mitochondrial antiviral-signaling protein), also known as IPS1, KIAA1271, VISA or CARDIF, is a 540 amino acid protein that contains one CARD domain and several transmembrane domains, and localizes to the outer mitochondrial membrane. Expressed throughout the body with highest ex-pression in liver, heart, placenta, skeletal muscle and peripheral blood leuk-ocytes, MAVS functions downstream of proteins, such as RIG-I, that detect double-stranded (ds) viral replication and is required for proper immune re-sponse against ds viral infection. MAVS is thought to activate pathways that lead to the induction of antiviral cytokines and may protect the cells from viral-induced apoptosis. MAVS function can be inactivated via cleavage by a protease complex that degrades the CARD and transmembrane domains, thereby preventing MAVS from interacting with other proteins. Three isoforms of MAVS are expressed due to alternative splicing events.

DETAILS

  • Host: mouse
  • Type: Primary
  • Uniprot: Q7Z434
  • Clonality: Monoclonal
  • Conjugate: unconjugated
  • Applications: WB, IP, IF, IHC(P), ELISA
  • Human Gene Id: 57506
  • Protein Target: MAVS
  • Human Gene Name: MAVS
  • Species Reactivity: human

PROMOTION TERMS

Free sample available. Limit 3 free samples for each full size Santa Cruz Biotechnology primary antibody ordered. All samples must be different. Customer responsible for shipping costs.